false
0001787740
0001787740
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date
of earliest event reported): November 12,
2026
Valion
Bio, Inc.
(Exact name of Registrant as Specified in Its
Charter)
| Delaware |
001-41052 |
81-4016391 |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
|
|
1305 E. Houston Street,
Building 1, Suite 311 |
|
|
| San Antonio, Texas |
|
78205 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
| Registrant’s Telephone Number, Including Area Code: 888
276-6888 |
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value
$0.0001 per share |
|
VBIO |
|
The Nasdaq Stock
Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 12, 2026, the stockholders of Valion
Bio, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated 2021 Equity Incentive Plan (the
“2021 Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 272,000 shares (the “Plan
Amendment”). The Plan Amendment became effective upon stockholder approval. Except for the increase in the share reserve and related
conforming changes, the Plan Amendment did not change any other term or provision of the 2021 Plan.
Item 5.07 Submission of Matters to a Vote of
Security Holders.
On November 12, 2026, the Company held a special
meeting of stockholders in a virtual format (the “Special Meeting”). As of the close of business on October 15, 2026, the
record date for the Special Meeting, there were 2,155,637 shares of the Company’s common stock issued and outstanding and entitled
to vote. At the Special Meeting, 1,125,685 shares, or approximately 52.22% of the shares entitled to vote, were represented virtually
or by proxy, constituting a quorum. Holders of the Company’s Series A, Series B and Series C Non-Voting Convertible Preferred Stock
were not entitled to vote those shares on the matters presented at the Special Meeting.
The proposals are more fully described in the
Company’s Definitive Proxy Statement on Schedule 14A dated October 16, 2026 (the “Proxy Statement”). The description
of the 2021 Plan and the Plan Amendment under Proposal 2 in the Proxy Statement is incorporated by reference into Item 5.02 of this Current
Report.
Based on the final tabulation provided by Broadridge,
the voting results on the proposals presented at the Special Meeting were as follows:
Proposal No. 1: The Company’s stockholders
approved the proposal to grant discretionary authority to the Company’s board of directors (the “Board”) to amend the
Company’s amended and restated certificate of incorporation to effect a reverse stock split of all issued and outstanding shares
of common stock at a ratio of not less than 1-for-2 and not greater than 1-for-12, with the ratio to be determined by the Board at any
time within twelve months from the date of stockholder approval, without further stockholder approval or authorization.
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| 681,523 |
444,153 |
9 |
0 |
Proposal No. 2: The Company’s stockholders
approved the Plan Amendment to increase the number of shares of common stock authorized for issuance under the 2021 Plan by 272,000 shares.
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| 466,174 |
131,057 |
27 |
528,427 |
Proposal No. 3: The Company’s stockholders
approved the proposal to authorize the Board, in its discretion, to adjourn the Special Meeting to another place, or a later date or dates,
if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals.
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| 686,478 |
438,311 |
896 |
0 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
|
|
VALION BIO, INC. |
| |
|
|
|
| Date: |
November 16, 2026 |
By: |
/s/ Dean Zikria |
| |
|
|
Name: Dean Zikria
Title: Interim Chief Executive Officer |